Lead Product(s) : GNT0004
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Results Of Gene Therapy GNT0004 for Duchenne Muscular Dystrophy Presented
Details : GNT0004 is an AAV8 vector-based gene therapy containing a shortened version of the DMD gene encoding dystrophin, targeting treatment for patients with Duchenne muscular dystrophy.
Product Name : GNT0004
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 23, 2024
Lead Product(s) : GNT0004
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATA-200
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Bpifrance
Deal Size : $8.6 million
Deal Type : Financing
Details : The financing will be used to support company's clinical trials and manufacturing development programs, including ATA-200 gene therapy targeting γ-sarcoglycan (SGCG) related limb-girdle muscular dystrophy Type 2C/R5 (LGMD2C/R5).
Product Name : ATA-200
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 19, 2023
Lead Product(s) : ATA-200
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Bpifrance
Deal Size : $8.6 million
Deal Type : Financing
Lead Product(s) : PXL770
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PXL770 is a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. AMPK is a central regulator of multiple metabolic pathways leading to the control of lipid metabolism, glucose homeostasis and inflammation.
Product Name : PXL770
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2022
Lead Product(s) : PXL770
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable